Unknown

Dataset Information

0

Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.


ABSTRACT: AIMS/INTRODUCTION:Dipeptidyl peptidase-4 inhibitor has been proven to improve glycemic control and ?-cell function in latent autoimmune diabetes in adults (LADA). The potential immune modulation mechanism is still unknown. Thus, we tested T-lymphocyte subsets and expression of relevant transcription factors in LADA patients with sitagliptin intervention for up to 1-year. MATERIALS AND METHODS:A total of 40 LADA patients were randomly assigned to sitagliptin and/or insulin treatment (SITA group; n = 20) or insulin alone treatment (CONT group; n = 20). Peripheral blood mononuclear cells were isolated at baseline, 6 months and 12 months. The percentage of T-lymphocyte subsets (T helper 1, T helper 2, T helper 17 and regulatory T cells) tested by flow cytometry, and the messenger ribonucleic acid expression (T box expressed in T cells [T-BET], GATA binding protein 3 [GATA3], forkhead box protein 3 [FOXP3] and related orphan receptor C [RORC]) tested by real-time polymerase chain reaction were determined at baseline, 6 months and 12 months. RESULTS:The percentage of regulatory T cells in the SITA group was significantly lower than that of the CONT group at baseline. The percentage of T helper 2 cells was higher than that of the CONT group at 6 months and 12 months. At 12 months, the percentage of T helper 17 cells was lower in the SITA group than that of the CONT group. After a 1-year visit, the messenger ribonucleic acid expression levels of T-BET expressed in T cells and RORC in the SITA group were significantly lower than at baseline. Whereas that of RORC in the CONT group were significantly lower than that at baseline. CONCLUSIONS:The data confirmed that sitagliptin altered the phenotype of T cells and downregulated the expression of T-BET and RORC in LADA patients, and ameliorated glycemic control in LADA patients.

SUBMITTER: Wang X 

PROVIDER: S-EPMC6400151 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Altered T-cell subsets and transcription factors in latent autoimmune diabetes in adults taking sitagliptin, a dipeptidyl peptidase-4 inhibitor: A 1-year open-label randomized controlled trial.

Wang Xia X   Yang Lin L   Cheng Ying Y   Zheng Peilin P   Hu Jingping J   Huang Gan G   Zhou Zhiguang Z  

Journal of diabetes investigation 20180803 2


<h4>Aims/introduction</h4>Dipeptidyl peptidase-4 inhibitor has been proven to improve glycemic control and β-cell function in latent autoimmune diabetes in adults (LADA). The potential immune modulation mechanism is still unknown. Thus, we tested T-lymphocyte subsets and expression of relevant transcription factors in LADA patients with sitagliptin intervention for up to 1-year.<h4>Materials and methods</h4>A total of 40 LADA patients were randomly assigned to sitagliptin and/or insulin treatmen  ...[more]

Similar Datasets

| S-EPMC7993585 | biostudies-literature
| S-EPMC6613228 | biostudies-literature
| S-EPMC4764037 | biostudies-literature
| S-EPMC5686657 | biostudies-literature
| S-EPMC3889317 | biostudies-literature
| S-EPMC5630555 | biostudies-literature
2011-12-31 | E-MTAB-583 | biostudies-arrayexpress
| S-EPMC3320861 | biostudies-literature
| S-EPMC6079465 | biostudies-literature
| S-EPMC3043624 | biostudies-literature